title: Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).
abstract: OBJECTIVE
  Uterine papillary serous carcinoma (UPSC) is a rare subtype of endometrial carcinoma, characterized by a poor outcome. We sought to better analyze the effect of surgery and adjuvant therapies on this disease.
  
  
  METHODS
  A retrospective analysis was performed on the records of 138 women diagnosed with UPSC between 1986 and 2003 in the framework of the Rare Cancer Network.
  
  
  RESULTS
  Median age at diagnosis was 67 years. Pure UPSC was found in 107 patients and mixed histology in 30. Fifty-four patients had stage I, 20 stage II, 41 stage III and 23 stage IV disease. Median follow-up for the surviving patients was 44 months. Surgery was performed in 129 patients, after which 122 were rendered free of gross disease and comprised the adjuvant group. Of these, 23 received platinum-based chemotherapy. Radiotherapy was applied in 52 patients and 28 underwent combined chemo-radiotherapy. At last follow-up, 57 patients were alive free of disease, 10 were alive with disease, 62 died of disease, 8 died of other causes and 1 died due to toxicity. Five-year disease-free survival (DFS), disease-specific survival (DSS) and overall survival for the 122 patients treated with curative intent were 42%, 56% and 54%, respectively. In multivariate analysis, age, stage, histology and adjuvant chemotherapy were significant for DFS; age, stage and histology were significant for DSS. Radiotherapy reduced the pelvic recurrence rate from 29% to 14% (p=0.047).
  
  
  CONCLUSIONS
  UPSC harbours a moderate prognosis, with age, stage and histology as significant prognosticators. Conservative surgery followed by adjuvant chemotherapy and pelvic radiotherapy can be suggested as an appropriate treatment approach for patients treated with curative intent.
authors: Division of Oncology, Rambam Health Care Campus and Rappaport Faculty of Medicine, Technion, Haifa, Israel. h_goldberg@rambam.health.gov.il
authors: Hadassah
authors: H
authors: Goldberg
authors: Robert C
authors: RC
authors: Miller
authors: Roxolyana
authors: R
authors: Abdah-Bortnyak
authors: Mariana
authors: M
authors: Steiner
authors: Ferah
authors: F
authors: Yildiz
authors: Amichay
authors: A
authors: Meirovitz
authors: Salvador
authors: S
authors: Villà
authors: Philip M P
authors: PM
authors: Poortmans
authors: David
authors: D
authors: Azria
authors: Jamal
authors: J
authors: Zidan
authors: Mahmut
authors: M
authors: Ozsahin
authors: Ufuk
authors: U
authors: Abacioglu
authors: Douglas G
authors: DG
authors: Gold
authors: Amnon
authors: A
authors: Amit
authors: Ofer
authors: O
authors: Lavie
authors: I Lale
authors: IL
authors: Atahan
authors: Abraham
authors: A
authors: Kuten
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001918:Brachytherapy; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D018283:Cystadenocarcinoma, Papillary / Q000473:pathology / Q000628:therapy*; D018284:Cystadenocarcinoma, Serous / Q000473:pathology / Q000628:therapy*; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D012189:Retrospective Studies; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin